HLA-C and cancer: However, advancements in cancer immunotherapy, MS instruments, bioinformatics tools, NGS like long-read Oxford nanopore, artificial intelligence, and deep machine learning algorithms, and the increase in training data to bind MHC algorithms show promise in improving and facilitating various cancer immunotherapy platforms, including clinical studies.